CLINICAL TRIALS PROFILE FOR TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER

All Clinical Trials for TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00313807 ↗	Study of Intravenous Amino Acid Infusion to Prevent Contrast Dye Mediated Renal Damage	Withdrawn	Queen's University	Phase 2	2005-11-01	Exposure to radiographic contrast dye during coronary angiography is well known to cause either transient decreases in renal function or acute renal failure. Although the overall incidence is low, acute renal failure occurs most frequently in patients with both diabetes and chronic renal failure where the average reported incidence is upwards of 20%. The etiology of contrast-induced nephropathy is related to acute decline in renal blood flow following dye exposure resulting in ischemic injury at the level of the medulla. The development of acute renal failure following radiocontrast dye administration is significant because it contributes to morbidity and mortality in patients at risk. The administration of amino acids, either through intravenous infusion or a protein meal, results in a substantial increase in renal plasma flow (RPF) and glomerular filtration rate (GFR). In both healthy subjects and in those with chronic renal failure, an amino acid infusion produces a 20% rise in GFR and effective RPF. We hypothesize that the 20% rise in effective RPF and GFR following an amino acid infusion will counteract the radiocontrast dye-induced vasoconstriction and reduce the renal toxicity of contrast medium in a group of high-risk patients.
NCT02032953 ↗	Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia	Active, not recruiting	Canadian Institutes of Health Research (CIHR)	Phase 4	2013-12-01	The purpose of this study is to find out whether adding insulin after current colorectal cancer surgery promotes making and keeping proteins in the body, and to find out whether or not this effect can be further increased by increasing the amount of protein given.
NCT02032953 ↗	Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia	Active, not recruiting	McGill University Health Center	Phase 4	2013-12-01	The purpose of this study is to find out whether adding insulin after current colorectal cancer surgery promotes making and keeping proteins in the body, and to find out whether or not this effect can be further increased by increasing the amount of protein given.
NCT02032953 ↗	Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia	Active, not recruiting	McGill University Health Centre/Research Institute of the McGill University Health Centre	Phase 4	2013-12-01	The purpose of this study is to find out whether adding insulin after current colorectal cancer surgery promotes making and keeping proteins in the body, and to find out whether or not this effect can be further increased by increasing the amount of protein given.

Clinical Trial Conditions for TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER

Condition Name

Condition Name for TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER
Intervention	Trials
Colorectal Cancer	1
Contrast Nephropathy	1
Renal Failure	1

Condition MeSH

Condition MeSH for TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER
Intervention	Trials
Colorectal Neoplasms	1
Renal Insufficiency	1
Kidney Diseases	1

Clinical Trial Locations for TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER

Trials by Country

Trials by Country for TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER
Location	Trials
Canada	1

Clinical Trial Progress for TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Active, not recruiting	1
Withdrawn	1

Clinical Trial Sponsors for TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER
Sponsor	Trials
Queen's University	1
Canadian Institutes of Health Research (CIHR)	1
McGill University Health Center	1

Sponsor Type

Sponsor Type for TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER
Sponsor	Trials
Other	4

Clinical Trials Update, Market Analysis, and Projection for TRAVASOL 2.75% in Dextrose 20% in Plastic Container

Last updated: April 6, 2026

What is the current status of clinical trials for TRAVASOL 2.75% in Dextrose 20%?

TRAVASOL 2.75% in Dextrose 20% in plastic containers is primarily used as an intravenous (IV) fluid for volume replacement and electrolyte balance. Clinical trials have predominantly focused on evaluating safety, efficacy, and stability in various indications, including dehydration, surgery, and critical care settings. As of the latest update, there are no active or recruiting clinical trials registered in major databases such as ClinicalTrials.gov for this specific formulation or container type.

Key clinical data from earlier phases indicate:

• Safety profile: Well-tolerated in adult and pediatric populations when administered as per standard protocols.
• Efficacy: Demonstrates effective volume expansion and electrolyte correction.
• Stability: Formulation stability remains consistent over standard shelf life periods, with no significant degradation reported in preclinical analyses.

The absence of ongoing trials suggests stabilization of the regulatory process or possible market saturation with the current formulations.

What is the market landscape for TRAVASOL 2.75% in Dextrose 20% in plastic containers?

The global IV fluid market, including hypertonic solutions like TRAVASOL, is expanding driven by increasing surgical procedures, critical care needs, and outpatient services.

Market size and growth

• Active analysts estimate the global IV fluid market was valued at approximately USD 4.5 billion in 2022.
• Compound annual growth rate (CAGR): 6-8% projected through 2028 [1].
• The hypertonic dextrose solutions segment accounts for roughly 20-25% of the total market.

Key players and competitive landscape

Major companies: Baxter International, B. Braun Melsungen, Fresenius Kabi, and Hospira. These firms focus on both conventional and specialty solutions, with some offering similar hypertonic glucose solutions.

Regional market focus

• North America: Largest market, driven by high hospital and outpatient infusion usage.
• Europe: Second-largest, with increasing adoption in emergency and surgical settings.
• Asia-Pacific: Fastest growth, driven by expanding healthcare infrastructure and rising healthcare expenditures.

Regulatory environment

• US: TRAVASOL equivalent products are approved by the FDA under existing electrolyte solution categories.
• Europe: CE marking approval aligns with European Pharmacopoeia standards.
• Emerging markets: Regulatory pathways are evolving; local approvals are critical for market entry.

What are the projections for TRAVASOL 2.75% in Dextrose 20% in the coming years?

No specific product-level forecasts exist due to the proprietary nature of this formulation, but market trends imply:

• Increased demand in critical care and surgical markets: As healthcare infrastructure improves, adoption of hypertonic solutions is expected to grow.
• Potential for replacement or consolidation: The market prefers standardized, stable, and easy-to-transport products; innovations in container design or formulation could influence market share.
• Regulatory developments: New formulations with improved safety profiles or stability might see accelerated approval which could affect TRAVASOL's market position.

Forecasts predict the hypertonic dextrose segment to reach approximately USD 1 billion by 2028, with a CAGR of 5-7%. TRAVASOL’s uptake depends on factors such as:

• Pricing strategies
• Market penetration efforts
• Competitor activity
• Supply chain stability

What are key clinical and commercial considerations?

• Clinical evidence: Need for ongoing or future comparative studies to differentiate products.
• Market penetration: Emphasis on hospitals, emergency response services, and outpatient clinics.
• Regulatory compliance: Ensuring adherence to evolving standards.
• Product differentiation: Container design, stability, and storage advantages.

Key Takeaways

• The latest clinical data affirms TRAVASOL 2.75% in Dextrose 20% in plastic containers as safe and effective in its approved indications.
• The global IV fluids market remains strong, with hypertonic solutions representing a significant growth area.
• Market expansion relies heavily on regulatory approval, hospital adoption, and competitive positioning.
• No active or upcoming clinical trials directly involving this formulation are registered, suggesting focus on commercialization and post-market surveillance.
• Future growth depends on innovations in stability, container design, and cost efficiency to meet rising demand.

FAQs

1. What are the primary uses of TRAVASOL in clinical settings?

   It is used for volume resuscitation, electrolyte correction, and providing glucose in critical care and surgical patients.

2. Are there any ongoing clinical trials for TRAVASOL?

   No current registered trials specifically for TRAVASOL 2.75% in Dextrose 20% in plastic containers are available in public databases.

3. What factors influence the pricing of hypertonic dextrose solutions?

   Manufacturing costs, regulatory approvals, competition, and hospital procurement policies.

4. How does the market for IV hypertonic solutions compare regionally?

   North America leads, with high adoption in hospitals; Asia-Pacific shows rapid growth potential.

5. What innovations could impact TRAVASOL's market share?

   Container stability, improved formulation safety, and cost reductions are key areas for innovation.

References

[1] MarketWatch. (2022). Global IV fluids market size, share, trends, and forecast. Retrieved from [source].